Tocilizumab holds firm as steroid-sparing agent in giant cell arteritis Source: Warrington K. When should biologic agents be introduced in giant cell arteritis and for how long should they be given? Presented at: Biologic Therapies Summit IX; May 21-23, 2021 (virtual meeting). Disclosures: Warrington reported no relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe ADDED TO EMAIL ALERTS You've successfully added to your alerts. You will receive an email when new content is published. Back to Healio